Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APYX OTCMKTS:HYBT NASDAQ:LUNG NASDAQ:VANI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPYXApyx Medical$1.99-1.5%$2.14$0.76▼$2.73$75.26M1.4378,275 shs17,889 shsHYBTHeyu Biological Technology$0.20$0.13$0.00▼$3.40$20.65M-17.745,371 shs1 shsLUNGPulmonx$1.71-2.8%$2.34$1.47▼$9.37$69.68M0.43856,319 shs398,425 shsVANIVivani Medical$1.15-2.5%$1.35$0.91▼$1.80$68.13M3.12135,620 shs63,094 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPYXApyx Medical0.00%-4.78%+13.71%+22.84%+49.62%HYBTHeyu Biological Technology0.00%0.00%+45.99%-1.23%-20.00%LUNGPulmonx0.00%+1.18%+6.21%-45.37%-76.64%VANIVivani Medical0.00%-7.26%-13.53%-6.50%-12.21%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAPYXApyx Medical1.8792 of 5 stars0.03.00.04.23.01.70.6HYBTHeyu Biological TechnologyN/AN/AN/AN/AN/AN/AN/AN/ALUNGPulmonx4.0859 of 5 stars4.34.00.00.02.53.31.3VANIVivani Medical2.3713 of 5 stars3.53.00.00.02.81.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPYXApyx Medical 2.67Moderate BuyN/AN/AHYBTHeyu Biological Technology 0.00N/AN/AN/ALUNGPulmonx 2.56Moderate Buy$7.66348.20% UpsideVANIVivani Medical 3.00Buy$4.00247.83% UpsideCurrent Analyst Ratings BreakdownLatest HYBT, LUNG, APYX, and VANI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/1/2025LUNGPulmonxWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$6.00 ➝ $3.007/31/2025LUNGPulmonxLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$12.00 ➝ $8.007/31/2025LUNGPulmonxStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$16.00 ➝ $5.007/31/2025LUNGPulmonxD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$17.00 ➝ $16.007/31/2025LUNGPulmonxPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOverweight ➝ Neutral$9.00 ➝ $2.50(Data available from 9/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPYXApyx Medical$46.51M1.62N/AN/A$0.38 per share5.24HYBTHeyu Biological Technology$80K258.12N/AN/A$0.38 per share0.53LUNGPulmonx$90.55M0.77N/AN/A$2.17 per share0.79VANIVivani MedicalN/AN/AN/AN/A$0.30 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPYXApyx Medical-$23.46M-$0.45N/AN/AN/A-37.11%-158.22%-28.30%11/7/2025 (Estimated)HYBTHeyu Biological Technology-$270KN/A0.00∞N/A-453.55%-6.43%-4.43%N/ALUNGPulmonx-$56.39M-$1.43N/AN/AN/A-62.88%-69.76%-36.26%10/29/2025 (Estimated)VANIVivani Medical-$23.49M-$0.45N/AN/AN/AN/A-194.66%-68.64%11/12/2025 (Estimated)Latest HYBT, LUNG, APYX, and VANI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025VANIVivani Medical-$0.10-$0.12-$0.02-$0.12N/AN/A8/7/2025Q2 2025APYXApyx Medical-$0.0933-$0.09+$0.0033-$0.09$11.69 million$11.37 million7/30/2025Q2 2025LUNGPulmonx-$0.40-$0.38+$0.02-$0.38$23.46 million$23.86 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPYXApyx MedicalN/AN/AN/AN/AN/AHYBTHeyu Biological TechnologyN/AN/AN/AN/AN/ALUNGPulmonxN/AN/AN/AN/AN/AVANIVivani MedicalN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPYXApyx Medical4.614.723.95HYBTHeyu Biological TechnologyN/A0.350.34LUNGPulmonx0.545.354.63VANIVivani MedicalN/A1.301.30Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPYXApyx Medical55.33%HYBTHeyu Biological TechnologyN/ALUNGPulmonx91.04%VANIVivani Medical6.78%Insider OwnershipCompanyInsider OwnershipAPYXApyx Medical15.20%HYBTHeyu Biological Technology89.24%LUNGPulmonx6.80%VANIVivani Medical46.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPYXApyx Medical27037.82 million32.07 millionOptionableHYBTHeyu Biological Technology6103.25 million11.11 millionNot OptionableLUNGPulmonx25040.75 million37.98 millionOptionableVANIVivani Medical2059.24 million31.76 millionOptionableHYBT, LUNG, APYX, and VANI HeadlinesRecent News About These CompaniesA brewing GLP-1 showdown, from Big Pharma pills to a biotech implantAugust 27, 2025 | finance.yahoo.comOzempic for dogs? I’d happily put my food-obsessed golden retriever on ‘Wagovy’August 24, 2025 | aol.comAAre weight-loss jabs for dogs the next big thing? Scientists exploring new solutions for pet obesityAugust 22, 2025 | msn.comOzempic For Pets: New Drug Being Tested For Animal Obesity - Here's What We KnowAugust 22, 2025 | msn.comCould Dogs Get Their Version Of Ozempic? Scientists Test "Ozempup" For Pet ObesityAugust 21, 2025 | ndtv.comNAfter Ozempic, is “Ozempup” on the way? Scientists explore weight-loss jabs for obese pet dogs-- All details hereAugust 21, 2025 | msn.comVivani Medical, Inc. to Present at H.C. Wainwright 27th Annual Global Investment Conference on Innovative Drug Implant TechnologyAugust 20, 2025 | quiverquant.comQVivani Medical CEO Adam Mendelsohn to Present at the H.C. Wainwright 27th Annual Global Investment Conference on September 10, 2025August 20, 2025 | globenewswire.comFido get fat? Ozempic for dogs could hit the market in three yearsAugust 19, 2025 | msn.comVivani Medical (NASDAQ:VANI) Stock Price Down 0.8% After Earnings MissAugust 15, 2025 | marketbeat.comVivani Medical (NASDAQ:VANI) Announces Quarterly Earnings ResultsAugust 15, 2025 | marketbeat.comVivani closes $10M financing, advances GLP-1 implantAugust 14, 2025 | drugdeliverybusiness.comDVivani Medical, Inc.: Vivani Medical Provides Business Update Including $10M Equity Financing and Reports Second Quarter 2025 Financial ResultsAugust 14, 2025 | finanznachrichten.deVivani Medical Reports Q2 2025 Results and $10M FinancingAugust 13, 2025 | tipranks.comVivani Medical Provides Business Update Including $10M Equity Financing and Reports Second ...August 13, 2025 | bakersfield.comBVivani Medical Secures $10M Through Share Purchase AgreementAugust 13, 2025 | msn.comVivani Medical Provides Business Update Including $10M Equity Financing and Reports Second Quarter 2025 Financial ResultsAugust 13, 2025 | globenewswire.comVivani Medical (VANI) to Release Quarterly Earnings on TuesdayAugust 6, 2025 | marketbeat.comVivani Medical, Inc. (NASDAQ:VANI) Sees Large Growth in Short InterestAugust 2, 2025 | marketbeat.com3 Penny Stocks With Market Caps Over $30M To ConsiderJuly 16, 2025 | finance.yahoo.comVivani Medical Insiders Added US$5.29m Of Stock To Their HoldingsJune 30, 2025 | uk.finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeHYBT, LUNG, APYX, and VANI Company DescriptionsApyx Medical NASDAQ:APYX$1.99 -0.03 (-1.49%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$1.98 -0.01 (-0.75%) As of 08/29/2025 04:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Apyx Medical Corporation, an energy technology company, engages in the design, development, and manufacture of medical devices in the United States and internationally. The company operates through two segments: Advanced Energy and Original Equipment Manufacturing (OEM). It offers Helium Plasma Generator for delivery of RF energy and helium plasma to cut, coagulate, and ablate soft tissue during open and minimally invasive surgical procedures. The company's Helium Plasma Technology products are marketed and sold under the Renuvion name in the cosmetic surgery market and under the J-Plasma name in the hospital surgical market. It also develops and manufactures various hand pieces for open and laparoscopic procedures; and OEM generators, as well as related accessories. The company was formerly known as Bovie Medical Corporation and changed its name to Apyx Medical Corporation in January 2019. Apyx Medical Corporation was incorporated in 1982 and is based in Clearwater, Florida.Heyu Biological Technology OTCMKTS:HYBT$0.20 0.00 (0.00%) As of 08/29/2025Hong Chang Biotechnologies (HK) Limited was incorporated in 2023 and is based in Kowloon, Hong Kong. Hong Chang Biotechnologies (HK) Limited operates as a subsidiary of Zengqiang Investment Limited. As of September 4, 2023, Hong Chang Biotechnologies (HK) Limited operates as a subsidiary of Heyu Biological Technology Corporation.Pulmonx NASDAQ:LUNG$1.71 -0.05 (-2.84%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$1.71 +0.00 (+0.23%) As of 08/29/2025 07:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. It also offers StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. The company serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.Vivani Medical NASDAQ:VANI$1.15 -0.03 (-2.54%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$1.20 +0.05 (+4.35%) As of 08/29/2025 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Vivani Medical, Inc., a clinical stage company, develops various implants that treat chronic diseases with high unmet medical need. It engages in developing a portfolio of miniature drug implants to deliver minimally fluctuating drug profiles; and implantable visual prostheses devices to deliver useful artificial vision to blind individuals. The company is headquartered in Emeryville, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 08/25 - 08/29 Ollie’s Bargain Outlet: Buy it While It’s Still a Bargain Tencent Music Stock Outshines Spotify as China’s Music Giant With Shares Near Highs, Here's to Watch in Broadcom's Q3 Report Best Buy Marketplace: Potential Growth Catalyst or Risky Gimmick? DICKS’s Sporting Goods Stock Dropped After Earnings—Is It a Buy? CrowdStrike at a Crossroads: AI Halo vs. Risks Snowflake’s Snowballing Business and Robust Stock Price Outlook Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
